Ask AI
Atopic dermatitis burden and topicals

CE / CME

Addressing the Atopic Dermatitis Burden: Selecting the Right Nonsteroidal Topical Therapy

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Released: September 02, 2025

Expiration: September 01, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 9-mo-old infant presents with moderate atopic dermatitis affecting cheeks and trunk. Parents are hesitant about steroids and prefer a nonsteroidal option. Which topical therapy is FDA-approved for this age group and supported by data from phase III pediatric trials?

2.

A 28-yr-old man with moderate AD presents with severe pruritus and insomnia. He has tried crisaborole in the past with limited success. You consider a topical JAK inhibitor. Which of the following statements about ruxolitinib cream is best supported by clinical trial data?

3.

A 10-yr-old child with mild to moderate AD involving the antecubital fossae and neck is being considered for topical roflumilast 0.15% cream. You review the results of the INTEGUMENT-1 and INTEGUMENT-2 clinical trials to guide evidence-based decision-making. Which of the following local adverse effects is most commonly associated with roflumilast 0.15% cream use?